William Blair Issues Pessimistic Forecast for APLT Earnings

Applied Therapeutics, Inc. (NASDAQ:APLT) – Analysts at William Blair reduced their Q2 2025 earnings estimates for shares of Applied Therapeutics in a research report issued to clients and investors on Tuesday, October 22nd. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.10). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. William Blair also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.36) EPS.

Applied Therapeutics (NASDAQ:APLT) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $10.00 million.

A number of other research firms have also recently commented on APLT. Royal Bank of Canada restated an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research note on Wednesday, July 17th. Leerink Partners raised their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Finally, Citigroup lifted their price objective on shares of Applied Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.50.

Applied Therapeutics Trading Down 5.5 %

NASDAQ APLT opened at $8.43 on Thursday. Applied Therapeutics has a 12 month low of $1.79 and a 12 month high of $9.39. The stock has a market cap of $963.27 million, a price-to-earnings ratio of -4.58 and a beta of 2.04. The company’s 50 day moving average is $7.19 and its two-hundred day moving average is $5.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Applied Therapeutics in the second quarter valued at $920,000. Bank of New York Mellon Corp purchased a new position in shares of Applied Therapeutics in the second quarter valued at $1,325,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Applied Therapeutics by 17.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock valued at $10,676,000 after purchasing an additional 333,278 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of Applied Therapeutics in the second quarter valued at $3,414,000. Finally, Algert Global LLC purchased a new position in Applied Therapeutics during the second quarter worth $110,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Shoshana Shendelman sold 300,000 shares of Applied Therapeutics stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $5.98, for a total transaction of $1,794,000.00. Following the sale, the chief executive officer now owns 5,167,853 shares in the company, valued at $30,903,760.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.60% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.